Last reviewed · How we verify
MP0420
MP0420 is a monoclonal antibody that targets and blocks PD-1 on T cells to enhance anti-tumor immune responses.
MP0420 is a monoclonal antibody that targets and blocks PD-1 on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | MP0420 |
|---|---|
| Also known as | ensovibep |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MP0420 binds to programmed death receptor 1 (PD-1) on the surface of T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the inhibitory signal that tumors use to evade immune attack, thereby restoring T cell activation, proliferation, and anti-tumor cytotoxic function.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Fatigue
- Diarrhea
- Rash
- Immune-related adverse events
Key clinical trials
- A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 (PHASE2, PHASE3)
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
- Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19) (PHASE1)
- Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP0420 CI brief — competitive landscape report
- MP0420 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI